| Literature DB >> 32198643 |
S I Croon1,2, A Angkasuwan1,2, A H van Straten1, A Khamooshian3, T W Elenbaas1, M A Soliman-Hamad4.
Abstract
OBJECTIVES: Aortic valve endocarditis is occasionally complicated by periannular spreading of the infection and abscess formation, leading to a more aggressive course of the disease and life-threatening complications. This retrospective observational study investigated the long-term outcomes of patients with this complication, which was surgically managed with annular reconstruction and aortic valve replacement.Entities:
Keywords: Aortic root; Aortic valve replacement; Endocarditis (all infectious agents); Heart valve
Year: 2020 PMID: 32198643 PMCID: PMC7270477 DOI: 10.1007/s12471-020-01409-x
Source DB: PubMed Journal: Neth Heart J ISSN: 1568-5888 Impact factor: 2.380
Basic characteristics (n = 69)
| Baseline characteristics | |
|---|---|
| Age, years | 58 ± 15 |
| Male gender | 56 (81) |
| Body mass index, kg/m2 | 26.4 ± 4.5 |
| Body surface area, m2 | 1.9 ± 0.2 |
| Diabetes mellitus | 8 (12) |
| Renal failure | 23 (33) |
| Hypertension | 24 (35) |
| Chronic obstructive pulmonary disease | 5 (7) |
| Transient ischaemic attack/stroke | 9 (13) |
| Peripheral vascular disease | 5 (7) |
| Impaired left ventricular function: | 12 (17) |
| Native valve endocarditis | 35 (51) |
| Prosthetic valve endocarditis | 34 (49) |
| Emergency | 46 (67) |
| Re-operation | 34 (49) |
Data are expressed as mean ± standard deviation or number (%)
Fig. 1Kaplan-Meier curve: overall survival of the study population
Operative data and hospital stay
| Operative procedure | |
|---|---|
| AVRa | 56 (81) |
| AVR + CABG | 4 (6) |
| AVR + MVPa | 5 (7) |
| AVR + MVR | 3 (4) |
| AVR + CABG + MVP | 1 (1) |
| Mechanical | 50 (72) |
| Bioprosthetic | 19 (28) |
| Left coronary cusp | 8 (12) |
| Right coronary cusp | 5 (7) |
| Non-coronary cusp | 18 (26) |
| Multiple locations | 19 (28) |
| – Commissure involved | 3 (4) |
| – No commissure involved | 16 (23) |
| Only commissural | 7 (10) |
| Other | 5 (7) |
| Unknown | 7 (10) |
| Aortic clamp time, min | 110 ± 40 |
| Cardiopulmonary bypass time, min | 157 ± 70 |
| ICU stay, daysb | 2 |
| Hospital stay, days | 40 |
Data are expressed as mean ± standard deviation, number (%), or median (25–75% interquartile range)
AoV aortic valve, AVR aortic valve replacement, CABG coronary artery bypass grafting, ICU intensive care unit, MV mitral valve, MVP mitral valve repair
aEither primary operation or re-operation
bIncluding 2nd ICU stay (10 patients)
Microorganisms overview
| Offending microorganisms | |
|---|---|
| Streptococci | 19 (28) |
| Staphylococci | 19 (28) |
| Propionibacteria | 14 (20) |
| Other | 11 (16) |
| Unknown | 2 (3) |
| Tissue and/or blood culture negative | 4 (6) |
Postoperative complications & long-term outcome
| Complication | |
|---|---|
| Re-exploration for bleeding | 10 (15) |
| Pulmonary complications | 19 (28) |
| Cerebrovascular accident | 5 (7) |
| 30-day mortality | 9 (13) |
| 120-day mortality | 11 (16) |
| Overall mortality | 25 (36) |
| Pacemaker implantation | 23 (33) |
| Reinfection | 8 (12) |
| Re-intervention | 7 (10) |
Comparison of studies concerning management and outcomes of aortic valve endocarditis complicated by periannular abscess
| Reference | NVE vs PVE | Prosthesis | Offending Microorganisms | Mortality | Freedom from re-endocarditis | Freedom from re-operation | Survival | Comment | |
|---|---|---|---|---|---|---|---|---|---|
| Present study | 69 | 51–49% | 28–72% | Staphylococci: 28% Streptococci: 28% Enterococci: 4% | 13% (30-day) 16% (120-day) 36% (overall) | 83.5 ± 13.3% (10 years) | 85.9 ± 10.6% (10 years) | 69 ± 12% (5 years) 56 ± 14% (10 years) | |
| Kirali (2016) [ | 27 | 78–22% | 7–36% | Staphylococci: 37% Streptococci: 15% Enterococci: 11% | 22% (hospital) 26% (30-day) | 63 ± 6% (5 years) 59 ± 7% (10 years) | Inclusion ARR patients | ||
Takahashi (2013) [ | 25 | 68–32% | 36–64% | Staphylococci: 48% Streptococci: 16% Enterococci: 12% | 20% (30-day) | 100% (3 years) | 100% (3 years) | 80 ± 8% (3 years) | Patients with LV-Ao discontinuity |
Leontyev (2012) [ | 172 | 56–44% | 82–11% | Staphylococci: 40% Streptococci: 23% Enterococci: 15% | 25% (30-day) | 80 ± 4% (5 years) | 50 ± 4% (5 years) | Ao allograft 7.5% | |
David (2007) [ | 135 | 51–49% | 41–49% | Staphylococci: 46% Streptococci: 26% Enterococci: 4% | 16% (operative) | 88 ± 3% (5 years) 82 ± 4% (10 years) 82 ± 4% (15 years) | 96 ± 2% (5 years) 84 ± 5% (10 years) 72 ± 9% (15 years) | 71 ± 4% (5 years) 57 ± 5% (10 years) 43 ± 6% (15 years) | Ao allograft 10% |
Naqvi (2005) [ | 45 | 47–53% | Staphylococci: 56% Streptococci: 9% Enterococci: 16% | 31% (hospital) | 62% (1 year) | 37 (82%) patients had surgery | |||
Anguera (2005) [ | 67 | 60–40% | Staphylococci: 36% Streptococci: 28% Enterococci: 12% | 19% (hospital) | IE with abscess vs without | ||||
Knosalla (2000) [ | 65 | 72–28% | 5–23% | Staphylococci: 40% Streptococci: 35% Enterococci: 12% | 24% (30-day) 89% (allograft) | 72% (11 years) 97% (allograft) | 73% (11 years) 90% (allograft) | 65% (11 years) 82% (allograft) | Ao allograft 72% |
d’Udekem (1996) [ | 70 | 49–51% | 43–51% | Staphylococci: 53% Streptococci: 30% Enterococci: 3% | 13% (operative) | 76 ± 10% (8 years) | 4.3% | 64 ± 8% (8 years) | Ao allograft 6% |
Ao aorta, ARR aortic root replacement, IE infective endocarditis, LV left ventricle, NVE native valve endocarditis, PVE prosthetic valve endocarditis
a Multicentre study